Clinical Trials Logo
  1. Home
  2. Trypanosomiasis, African
  3. NCT00489658

Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda — NECS  

Trypanosomiasis, African Clinical Trial

Official title:
Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda

Clinical Trial Summary

This case series study follows on a terminated randomised clinical trial in a nearby location of Uganda, in which the combination of eflornithine + nifurtimox showed very promising efficacy and safety. The study's purpose is to evaluate the efficacy and safety of this combination in a larger group of late-stage Human African trypanosomiasis (sleeping sickness) patients.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00489658
Study type Interventional
Source Epicentre
Contact
Status Terminated
Phase Phase 2/Phase 3
Start date October 2002
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01483170 - Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food Phase 1
Completed NCT03087955 - Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense Phase 2/Phase 3
Completed NCT03025789 - Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Phase 3
Completed NCT02571062 - Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation Phase 1
Terminated NCT00330148 - Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Phase 3
Recruiting NCT05433350 - Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients Phase 2/Phase 3
Withdrawn NCT05645822 - Screen and Treat Implementation for HAT Control
Completed NCT05947604 - DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan Phase 1
Completed NCT01533961 - Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 Phase 1
Completed NCT05256017 - Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects Phase 2/Phase 3
Completed NCT00802594 - A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Phase 2
Completed NCT00146627 - Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Phase 3